Routine use of hydroxocobalamin should be considered for victims of smoke inhalation, Vanderbilt researchers suggest.

Paul Bieniasz, Ph.D., a pioneer in the study of retroviruses, will deliver the next Flexner Discovery Lecture on Thursday, March 9.

Vanderbilt researchers hope their new method to describe cells will be widely adopted and used to generate a “Who’s Who” database of cell types.

The protein beta-catenin may be a good target for therapies to treat lung disease that is a common complication of preterm birth.

A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.

Josep Dalmau, M.D., Ph.D., renowned for his studies of immune disorders affecting the brain and spinal cord, will deliver the next Flexner Discovery Lecture on Thursday, Feb. 23.